ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 282 entries already.
London-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s gene therapy program, including its progression toward clinical development.
Join us for the 2nd BIO-Europe in Cologne, Germany, November 9–11, 2026, the premier biopharma partnering event now transformed into a comprehensive forum for biotech leaders.
On 13–14 October 2026, BIOTECH SUMMIT AUSTRIA brings Europe’s biotech community to Innsbruck for high-level keynotes, policy insights, partnering and networking
in a landmark Alpine setting.
Professor Andreas Pahl took over as Chief Executive Officer of Simris Biologics GmbH in mid-July. The subsidiary of Swedish Simris Group based in Berlin, develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies.
Ariane de Ganck, PhD, took over the position as new Chief Scientific Officer (CSO) at Ardena. She started in 2019 at the Ghent-based CDMO/CRO.
Swedish life science company PeptiSystems has appointed Ida Nordberg as Chief Financial Officer (CFO). The appointment marks another milestone in the company’s development and further strengthens the organization as it enters its next phase of commercialization and international expansion
SLAS Europe 2026 in Vienna brought together over 1,500 delegates for three days of innovation and collaboration. As we look ahead, join us at upcoming Meet-Ups in Leiden and Tübingen, and mark your calendars for SLAS2027 in San Diego, California.
With the appointment of Russell Thomas as Chief Scientific Officer, Symeres and Axxam are further strengthening their strategic collaboration. The goal is to provide pharmaceutical and biotechnology companies with an integrated platform for drug discovery and development from a single source.
By appointing Olav Hellebø as Chief Executive Officer, biotechnology company Exonate Ltd. aims to accelerate the clinical development of its lead candidate for diabetic eye disease.
Drug discovery depends on more than breakthrough science alone. Progress increasingly emerges from connected ecosystems where academia, biotech, pharma, CROs and technology providers can openly exchange ideas, challenge assumptions and accelerate innovation together.